Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Acadia Healthcare Company, Inc.

ACAD

FAVORABLE

May 27, 2026

Research Conclusion

At $24.65/share, ACAD is deeply discounted due to DOJ investigation overhang, not fundamentals. Base-case intrinsic value is $38-43/share on a 9x forward EBITDA basis. The 55-75% valuation gap should resolve upon legal clarity. With activist investors creating an M&A floor at $30-42 and a 1:3 risk/reward, the risk-adjusted expected value is approximately $39/share (+58%). Severe downside (5% probability) of $3-10/share if criminal charges trigger Medicaid exclusion requires position sizing discipline.

Company Overview & Moat Assessment

Acadia Healthcare Company, Inc. (NASDAQ: ACAD) is the largest publicly traded pure-play behavioral health operator in the United States, operating 277 facilities in 40 states and Puerto Rico, including 174 DEA-licensed Comprehensive Treatment Centers (CTCs) serving 74,000 opioid-use-disorder patients daily. Revenue of $3.3B (FY2025) splits across acute inpatient psychiatric care (~57%), residential treatment (~17%), CTC medication-assisted treatment (~18%), and outpatient (~8%). Funding is 58% Medicaid, 25% commercial, 14% Medicare. After a capital-heavy growth phase (FY2022-2024 peak CapEx $690M), the company pivoted in late 2025 to cash-flow-first operations: CapEx cut 60%, five underperforming facilities closed, 400 employees laid off, returning CEO Debbie Osteen installed for operational discipline. The company carries $2.5B long-term debt (3.9x net debt/EBITDA) and faces ongoing DOJ Criminal Division and SEC investigations active since at least 2022.

▲ Bull Case

  • ◆Legal clears via DPA + civil settlement; stock re-rates from 7-8x to 10-11x forward EBITDA, reaching ~$58/share (+135%) on $720M FY2027 EBITDA at 10.5x multiple
  • ◆CapEx discipline creates FCF inflection; $200M+ FCF on $2.3B market cap yields 8.7% FCF yield by FY2027, supporting $43-54/share valuation at 4-5% healthcare operator FCF yield norms
  • ◆CTC spin-off or strategic sale at 9-10x EBITDA nets $3.0-3.6B equity value (~$33-39/share), with 20-30% control premium yielding $40-50/share takeout price

▼ Bear Case

  • ◆Medicaid rate cuts spread beyond NY to 3+ large states (CA, TX, FL); cumulative $75-100M EBITDA headwinds; revenue growth slows to 3-4%; margins compress to 16-17%; FCF stays near zero; stock drifts to ~$19/share
  • ◆CapEx guidance slips with management's track record of $90-140M overruns; FY2026 CapEx comes in at $310-340M vs. $267M guide; FCF thesis delayed 12-18 months; ongoing litigation extends legal payments; each miss extends multiple-discount period
  • ◆DOJ investigation extends into 2027-2028 with no resolution visible; management distracted by compliance obligations; capital allocation improvements slow; investor fatigue sets in; stock trades at 7x EV/EBITDA for 18+ months
Primary Debate on Wall Street

“Consensus is bullish (Buy rating, average PT $22.67), but analyst community divides on: (1) What is DOJ Criminal exposure and can company survive? Bears cite Criminal Division qualitative difference vs. prior $19.85M settlement; bulls argue government has strong incentives to preserve largest behavioral health provider network and rarely imposes Medicaid exclusion in settlements. (2) Is 2026 CapEx guide credible given $90-140M FY2024 overrun? Bulls cite changed incentives: activist oversight, new CFO, explicit FCF focus in compensation. (3) Can EBITDA margins recover to 19-21%? Street consensus is ~18.7% by FY2028 vs. our base case 20.0%; debate turns on whether labor inflation is structural or cyclical and de novo maturation delivers expected operating leverage.”

Top Catalysts
  • ◆DOJ/SEC investigation update — DPA announcement, scope narrowing, or settlement discussion is primary binary catalyst; could add 30-50% to stock value immediately
  • ◆FY2026 CapEx delivery — Q2/Q3 confirmation at $267M guide validates FCF inflection thesis and removes capital allocation doubt
  • ◆Q2/Q3 2026 earnings beats — Each quarter of revenue/EBITDA beats reduces uncertainty premium and supports base-case narrative
  • ◆Strategic review announcement — Khrom/Engine formal demand or board response creates M&A premium catalyst; talks likely given activist engagement and new CEO credibility
  • ◆De novo facility maturation — FY2025/2026 vintage de novos reaching occupancy; $50M startup loss drag becomes positive EBITDA contribution
Top Risks
  • ◆DOJ Criminal charges filed with Medicaid exclusion proceedings (10% probability, existential impact) — formal indictment triggering exclusion review destroys revenue base and enterprise value simultaneously
  • ◆Medicaid rate cuts spread beyond NY to 3+ states within 12 months (25% probability, severe impact) — structural impairment of 57.7% of revenue base; margin recovery thesis breaks; debt coverage deteriorates
  • ◆CapEx guide slippage $50M+ in FY2026 (30% probability, moderate impact) — repeats capital allocation failure and delays FCF thesis timeline beyond investor patience
  • ◆Large DOJ settlement exceeds $750M in cash (30% probability, high impact) — pushes leverage to ~5x in stress scenario and risks covenant breach without dilutive equity raise
  • ◆Corporate Integrity Agreement adds $30-50M/yr compliance cost (40% probability, moderate impact) — structural drag on EBITDA margins extending into multi-year compliance period

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/ACAD/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.